http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1134290-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90245 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C20-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2001-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_183be2a8231e0e908a9f3f3cffe70b97 |
| publicationDate | 2001-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1134290-A2 |
| titleOfInvention | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| abstract | The present invention relates to novel screening methods which enable thenselection of selective serotonin reuptake inhibitor (SSRI) compounds which do notnpossess significant inhibitory potency towards cytochrome P450 enzymes, innparticular, CYP2D6. The present invention also relates to a method of generating anpharmacophore model for the CYP2D6 inhibitory activity of SSRI compounds; tonmethods for the discovery of molecules that are potential SSRI compounds which donnot possess significant inhibitory potency towards the CYP2D6 enzyme; to methodsnof modeling the features of the CYP2D6 pharmacophore useful in selecting SSRI'snwhich do not possess significant potency towards CYP2D6. Further, the inventionnalso relates to pharmaceutical compositions comprising an SSRI compound whichndoes not possess significant potency towards the CYP2D6 enzyme identified bynmethods of the invention; to the uses of an SSRI compound identified by the methodsnof the invention for the manufacture of medicaments and for the treatment of ancondition, a disorder or a disease in a mammal for which an SSRI compoundnidentified by the method of the invention is therapeutically useful. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113380340-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03038442-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03038442-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113380340-B |
| priorityDate | 2000-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 635.